Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
3 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Serum amyloid A as a biomarker: diagnostic relevance and clinical association with acute ischemic stroke(MEDICAL FACULTY - SKOPJE, 2025-10-16) ;Ivanovska, Slavjana; ; ;Kerala, CoskunKostovska, IrenaSerum amyloid A (SAA) is an acute-phase protein that circulates at low levels bound to high-density lipoproteins (HDL). During inflammation, its concentration rises sharply, altering HDL composition, lipid transport, and cholesterol metabolism. These changes contribute to vascular pathology, particularly atherosclerosis. Owing to its multifunctional role, SAA has gained attention as a potential biomarker in cardiovascular and cerebrovascular diseases, although its role in acute ischemic stroke (AIS) remains insufficiently clarified. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, CORRELATION OF PD-L1 GENE EXPRESSION WITH GRADE OF THE URINARY BLADDER CANCER(Македонско лекарско друштво = Macedonian medical association, 2023-12); ; ;Dohchev, Sasho; Abstract Introduction. Bladder cancer (BC) ranks fourth in the prevalence of malignancies in developed countries and is the eighth leading cause of cancer-related mortality in men. PD-L1, known for its role in inhibiting immune responses against malignant cells, has garnered significant attention in BC research. Methods. This study, comprising 45 patients with histopathologically confirmed urothelial carcinoma of the urinary bladder, analyzed the connection between histological grade and PD-L1 gene expression. The patient cohort was divided into 31 classified as low-grade and 14 as high-grade, with gender and age distribution well-balanced across the groups. PD-L1 expression was notably higher in the high-grade group (p=0.005), showing its potential clinical relevance as a biomarker. Results. Univariate logistic analysis revealed a robust correlation between histological grade and PDL1 expression, with high-grade patients exhibiting a 7.227-fold higher likelihood of increased PD-L1 expression. A predictive model for grade determination demonstrated commendable performance, boasting an area under the curve (AUC) of 0.788. Conclusion. These findings provide compelling evidence of a strong association between PD-L1 gene expression and the histological grade of bladder cancer. PD-L1 emerges as a potential biomarker, shedding light on a disease pathological grade, offering a significant clinical value for precise prognosis, and guiding tailored treatment strategies. These insights hold promise for improved disease management and patient outcomes. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Potential Role of Seven Proteomics Tissue Biomarkers for Diagnosis and Prognosis of Prostate Cancer in Urine(MDPI AG, 2022-12-16); ;Rusevski, Aleksandar; ;Popov, Zivko<jats:p>As the currently available tests for the clinical management of prostate cancer (PCa) are still far from providing precise diagnosis and risk stratification, the identification of new molecular marker(s) remains a pertinent clinical need. Candidate PCa biomarkers from the published proteomic comparative studies of prostate tissue (2002–2020) were collected and systematically evaluated. AZGP1, MDH2, FABP5, ENO1, GSTP1, GSTM2, and EZR were chosen for further evaluation in the urine of 85 PCa patients and controls using ELISA. Statistically significant differences in protein levels between PCa and BPH showed FABP5 (p = 0.019) and ENO1 (p = 0.015). A biomarker panel based on the combination of FABP5, ENO1, and PSA provided the highest accuracy (AUC = 0.795) for PCa detection. The combination of FABP5, EZR, AZGP1, and MDH2 showed AUC = 0.889 in PCa prognosis, with 85.29% of the samples correctly classified into low and high Gleason score (GS) groups. The addition of PSA to the panel slightly increased the AUC to 0.914. AZGP1, FABP5, and EZR showed significant correlation with GS, stage, and percentage of positive biopsy cores. Although validation using larger patient cohorts will be necessary to establish the credibility of the proposed biomarker panels in a clinical context, this study opens a way for the further testing of more high-quality proteomics biomarkers, which could ultimately add value to the clinical management of PCa.</jats:p>
